Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16964809 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2C19L3MBTL1DPP7GAA | |
| SCHEMBL3062227 | 0.85 | CYP3A4 (0.42) | CYP3A4CYP2C19L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL3062187 | 0.85 | CYP3A4 (0.42) | CYP3A4CYP2C19L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL3062191 | 0.85 | CYP3A4 (0.42) | CYP3A4CYP2C19L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL3067848 | 0.82 | DPP7 (0.56) | DPP7ALDH1A1MMP1MMP8 | |
| SCHEMBL8488986 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP2C19L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL5482918 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP2C19L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL6824021 | 0.81 | DPP7 (0.56) | CYP3A4CYP2C19L3MBTL1DPP7TSHR | |
| SCHEMBL28672211 | 0.79 | L3MBTL1 (0.42) | CYP3A4CYP2C19L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL16964806 | 0.78 | KDM4E (0.46) | CYP3A4CYP2C19L3MBTL1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | US | disclosed |
| EP-1893194-A4 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1893194-A1 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006127961-A1 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | PHKG1, PHKG2, PRKCH | CYP3A4 3771/4885CYP2C19 2617/4885L3MBTL1 2815/4885 |
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | PHKG1, PHKG2, PRKCH | CYP3A4 4175/4885CYP2C19 3517/4885L3MBTL1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.